Coiante Scott M 4

What Happened

• Scott M. Coiante, Chief Financial Officer of Lexicon Pharmaceuticals (LXRX), had 160,237 restricted stock units (derivative conversion/exercise) convert to common shares on February 28, 2026. Of those, 54,881 shares were withheld by the company to cover tax withholding obligations at $1.47 per share, a withholding value of $80,675. The conversion (code M) and withholding (code F) reflect a vesting/conversion event with net share settlement rather than an open-market sale or purchase.

Key Details

• Transaction date: February 28, 2026; Form 4 filed March 3, 2026.
• Primary action: Exercise/conversion of derivative (M) — 160,237 shares converted to common stock.
• Tax withholding: 54,881 shares withheld at $1.47/share = $80,675 (code F).
• Shares owned after transaction: Not specified in the filing.
• Footnotes: F1 = each restricted stock unit (RSU) converts to one share; F2 = company withheld shares to satisfy tax withholding; F3 = RSUs vest 1/3 each year on Feb 28 over three years following grant year.
• Filing timeliness: Report filed March 3, 2026 reporting the Feb 28 transaction (no late‑filing flag indicated in the document).

Context

• This was a routine RSU conversion with net settlement for taxes (company withheld a portion of issued shares) — not an open-market sale or purchase that would signal trading intent. Such withholding is common when restricted stock units vest and does not, by itself, indicate insider sentiment about the stock.